Core revenue grew 3.0% YoY, or 4.5% excluding respiratory testing revenue. However, the company's third quarter core revenue growth guidance of 2.0% to 3.0% appeared to disappoint investors, driving the sharp decline in shares. For the full year 2026, Danaher expects core revenue growth in the 3.0% to 4.0% range. The company's Biotechnology segment posted 2.5% core revenue growth, Life Sciences grew 5.5%, and Diagnostics increased 2.0%. Related articlesDanaher shares tumble despite earnings beatCiti pushes back Fed rate cuts to May after blowout January jobs reportNvidia's new Alpamayo project: What it means for Tesla?